

Shares of Recursion Pharmaceuticals jumped 7.2% in the afternoon session after the company aligned with the FDA on the design of its registrational Phase 3 trial of REC-4881, an investigational oral MEK1/2 inhibitor for the treatment of familial adenomatous polyposis (FAP).
According to a company press release, the trial's composite event-free survival primary endpoint will include the excision of adenomas 10 mm or larger throughout the GI tract. The release stated that adenomas of this size are associated with an increased risk of high-grade dysplasia and cancer, while modified Spigelman stage progression and total polyp burden will be included among secondary endpoints.
The release also noted that the trial is expected to enroll approximately 200 adults with FAP following colectomy or proctocolectomy and is on track to begin in the second half of 2027.
Recursion Pharmaceuticals’s shares are extremely volatile and have had 62 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
Recursion Pharmaceuticals is down 30.8% since the beginning of the year, and at $2.91 per share, it is trading 41.4% below its 52-week high of $4.96 from January 2026. Investors who bought $1,000 worth of Recursion Pharmaceuticals’s shares 5 years ago would now be looking at only $151.07.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.